世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

神経修復・再生市場：製品（神経調節デバイス（深部脳刺激、迷走神経刺激）、生体材料（神経導管、神経ラップ）、アプリケーション（神経切除、神経移植、幹細胞治療）別 - 2027年までの世界予測


Nerve Repair & Regeneration Market by Products (Neuromodulation Devices (Deep Brain Stimulation, Vagus Nerve Stimulation), Biomaterials (Nerve Conduits, Nerve Wraps), Application (Neurorrhaphy, Nerve Grafting, Stem Cell Therapy) - Global Forecast to 2027

世界の神経修復・再生市場は、2022年の65億米ドルから2027年には116億米ドルに達し、CAGR12.1％で推移すると予測されています。この市場の成長は、政府による神経疾患に関する研究支出の増加、市場参加者による神... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 図表数 言語
MarketsandMarkets
マーケッツアンドマーケッツ 		2022年6月2日 US$4,950
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		225 355 英語

日本語のページは自動翻訳を利用し作成しています。


　

サマリー

世界の神経修復・再生市場は、2022年の65億米ドルから2027年には116億米ドルに達し、CAGR12.1％で推移すると予測されています。この市場の成長は、政府による神経疾患に関する研究支出の増加、市場参加者による神経調節・神経刺激デバイスや生体材料への研究開発投資の増加によってもたらされます。また、老年人口が増加していることも、神経修復・再生製品の需要を高め、市場の成長を阻害しています。

"予測期間中に最も速い成長率で成長すると予想されるのは、バイオマテリアルとしてのセグメントです。"
製品タイプに基づき、神経修復・再生市場は、神経刺激・神経調節デバイスとバイオマテリアルに区分されます。生体材料セグメントは、政府および市場プレイヤーによる研究投資、研究開発費に牽引され、最も高いCAGRを記録すると予想されます。

"内部神経刺激と神経調節セグメントが分析期間中に最大のシェアを占めている。"
神経修復・再生市場は、神経刺激・神経調節用途に基づき、神経刺激・神経調節装置市場は、内部神経刺激・神経調節用途と外部神経刺激・神経調節用途に区分されます。神経損傷の増加や神経疾患の発生率の高さから、予測期間中は体内神経刺激療法が最も高いシェアを占めています。

「アジア太平洋地域は、調査期間中に最も高いCAGRを記録すると推定される。北米が市場シェアを独占すると予測される。
本レポートでは、神経修復・再生市場を、北米、欧州、アジア太平洋、その他の地域（中東・アフリカ、中南米）の4つの主要地域セグメントに分類しています。2021年には、大手プレイヤーの存在と高度な医療インフラにより、北米が最大のシェアを占めています。
アジア太平洋地域は、膨大な人口、経済成長、医療インフラと医療費の改善、神経疾患の高い認知度、需要の増加により、予測期間中に最も高い成長率で成長すると予測されます。

サプライサイドの一次面接の内訳（企業タイプ別、呼称別、地域別）。
- 企業タイプ別企業タイプ別： Tier 1 (32%) , Tier 2 (44%) , Tier 3 (24%)
- 役職別Cレベル(30%)、ディレクターレベル(34%)、その他(36%)
- 地域別北米 (50%)、欧州 (32%)、アジア太平洋 (10%)、その他の地域 (8%)

本レポートに掲載されているプレイヤー一覧
- メドトロニック（Medtronic, plc.(アイルランド)
- ボストン・サイエンティフィック・コーポレーション(米国)
- アボット・ラボラトリーズ（米国）
- アクソジェン・コーポレーション（米国）
- バクスター(米国)
- リヴァノヴァPLC（英国）
- インテグラライフサイエンス（米）
- ニューロネティクス社（米国）
- ネブロ社（米国）
- ニューロペース社（米国）
- ポリガニクス (オランダ)
- ソテリクス・メディカル・インク（米国）
- シナプスバイオメディカル社（米国）
- Aleva Neurotherapeutics SA（スイス）
- コラーゲンマトリックス社（米国）
- ケリメディカル（スイス）
- バイオウェーブゴーUSA（米国）
- ニューロシグマ社（米国）
- tVNS Technologies GmbH（ドイツ）
- ジーメル・メディカル（台湾）
- チェックポイントサージカル社（米国）
- レニショーPLC（英国）
- アラフェア・バイオサイエンス社（米国）
- エレクトロコア社（米国）

調査対象
本レポートでは、神経修復・再生市場を製品、用途、地域に基づいて調査しています。また、市場成長に影響を与える要因（ドライバー、阻害要因、機会、課題など）を分析しています。利害関係者向けに市場の機会や課題を評価し、市場リーダー向けに競争環境の詳細を提供しています。また、マイクロマーケットについて、その成長動向、展望、神経修復・再生市場全体への貢献度に関して調査しています。本レポートでは、4つの主要地域に関して、市場セグメントの収益を予測しています。

レポート購入の理由
本レポートは、以下のポイントに関する洞察を提供します。
- 市場の浸透。市場の上位16社が提供する神経修復・再生に関する包括的な情報。神経修復・再生市場を製品別、地域別に分析しています。
- 市場の発展。有利な新興市場に関する包括的な情報。本レポートでは、主要な地理的地域における様々な神経修復・再生の市場を分析しています。
- 市場の多様化。神経修復再生市場における新製品、未開拓の地域、最近の開発、投資に関する徹底的な情報。
- 競争力の評価。神経修復・再生市場における主要企業の市場シェアと戦略に関する詳細な評価

ページTOPに戻る


目次

1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
FIGURE 1 NERVE REPAIR & REGENERATION MARKET SEGMENTATION 38
1.3.2 YEARS CONSIDERED FOR THE STUDY 38
1.4 CURRENCY 39
TABLE 2 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES MADE 39
1.7 LIMITATIONS 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 43
TABLE 3 KEY DATA FROM PRIMARY SOURCES 44
2.1.2.2 Key industry insights 45
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 45
2.2 MARKET SIZE ESTIMATION 46
FIGURE 4 NERVE REPAIR & REGENERATION MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC PLC 47
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF NERVE REPAIR & REGENERATION PRODUCTS 48
FIGURE 6 CAGR PROJECTIONS 49
FIGURE 7 TOP-DOWN APPROACH 50
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
FIGURE 8 DATA TRIANGULATION 51
2.4 MARKET SHARE ANALYSIS 52
2.5 ASSUMPTIONS FOR THE STUDY 52
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 52
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 53
2.7 RISK ASSESSMENT 53
TABLE 4 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
FIGURE 9 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2022 VS. 2027 (USD BILLION) 54
4 PREMIUM INSIGHTS 59
4.1 NERVE REPAIR & REGENERATION MARKET OVERVIEW 59
4.2 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT & COUNTRY (2021) 59
4.3 NERVE REPAIR & REGENERATION MARKET, BY REGION (2022 VS. 2027) 60
FIGURE 19 NORTH AMERICA TO DOMINATE THE NERVE REPAIR & REGENERATION MARKET DURING THE FORECAST PERIOD 60
4.4 NERVE REPAIR & REGENERATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 21 NERVE REPAIR & REGENERATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 61
5.2.1.1 High incidence of nerve injuries 61
5.2.1.2 Rising focus on neuromodulation & neurostimulation technologies 62
5.2.1.3 Rising geriatric population and the subsequent increase in the prevalence of neurological disorders 62
5.2.1.4 Rising government support for research on neurological disorders 63
FIGURE 22 FUNDING FOR RESEARCH BY THE NIH (US) 63
5.2.2 OPPORTUNITIES 64
5.2.2.1 Emerging markets 64
FIGURE 23 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA, 2012–2019 64
5.2.2.2 Advances in stem cell therapy in nerve repair & regeneration 64
5.2.2.3 Growing research projects in neurology 65
FIGURE 24 RESEARCH PAPERS PUBLISHED (2011-2021) 65
TABLE 5 INDICATIVE LIST: NEUROMODULATION CLINICAL TRAILS 65
5.2.3 CHALLENGES 66
5.2.3.1 Donor-site morbidity 66
5.2.3.2 Difficulties in treating large nerve gaps 66
5.2.3.3 Stringent regulatory frameworks and time-consuming approval processes 66
5.2.3.4 Greater preference for drug therapies over nerve repair & regeneration products 66
5.2.3.5 Shortage of trained professionals 66
5.2.3.6 Product recalls 67
TABLE 6 MAJOR PRODUCT RECALLS 67
5.3 IMPACT OF COVID-19 ON THE NERVE REPAIR & REGENERATION MARKET 67
FIGURE 25 REVENUE OF NEUROMODULATION SEGMENT BY THE TOP THREE PLAYERS, 2019-2021 (USD MILLION) 68
5.4 PRICING ANALYSIS 69
TABLE 7 AVERAGE SELLING PRICES OF NERVE WRAP AND NERVE CONDUIT 69
TABLE 8 AVERAGE SELLING PRICES OF NERVE WRAP OF KEY COMPANIES 69
TABLE 9 AVERAGE SELLING PRICES OF NERVE CONDUITS OF KEY COMPANIES 69
6 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT 70
6.1 INTRODUCTION 71
TABLE 10 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2018–2020 (USD MILLION) 71
TABLE 11 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 71
6.2 NEUROSTIMULATION AND NEUROMODULATION DEVICES 71
TABLE 12 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 72
TABLE 13 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 72
TABLE 14 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 72
TABLE 15 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 72
6.2.1 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 73
TABLE 16 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 73
TABLE 17 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 73
TABLE 18 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 74
TABLE 19 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 74
6.2.1.1 Spinal cord stimulation devices 74
6.2.1.1.1 Increasing incidence of spinal cord injuries to support the growth of this segment 74
TABLE 20 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 75
TABLE 21 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 75
6.2.1.2 Deep brain stimulation devices 76
6.2.1.2.1 Rising incidence of neurodegenerative diseases among the senior population drives the growth of this segment 76
TABLE 22 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 76
TABLE 23 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 77
6.2.1.3 Vagus nerve stimulation devices 77
6.2.1.3.1 Increasing incidence of epilepsy to support the market growth for VNS devices 77
TABLE 24 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 77
TABLE 25 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 78
6.2.1.4 Sacral nerve stimulation devices 78
6.2.1.4.1 Increasing incidence of urological disorders to drive the growth of this segment 78
TABLE 26 SACRAL NERVE STIMULATION DEVICES OFFERED BY SOME MARKET PLAYERS 78
TABLE 27 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 79
TABLE 28 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 79
6.2.1.5 Gastric electrical stimulation devices 79
6.2.1.5.1 GES is mainly used for the treatment of GERD and gastroparesis 79
TABLE 29 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 80
TABLE 30 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 80
6.2.2 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 80
TABLE 31 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 80
TABLE 32 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 81
TABLE 33 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION BY REGION, 2018–2020 (USD MILLION) 81
TABLE 34 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 81
6.2.2.1 Transcutaneous electrical nerve stimulation devices 82
6.2.2.1.1 Extensive use in healthcare and low costs to support the growth of this segment 82
TABLE 35 TENS DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 82
TABLE 36 TENS DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 83
6.2.2.2 Transcranial Magnetic Stimulation Devices 83
6.2.2.2.1 Minimal patient discomfort associated with TMS to support the adoption of TMS devices 83
TABLE 37 TMS DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 83
TABLE 38 TMS DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 84
6.2.2.3 Respiratory Electric Stimulation Devices 84
6.2.2.3.1 Increasing incidence of spinal cord injuries to support the growth of this segment 84
TABLE 39 RES DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 84
TABLE 40 RES DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 85
6.3 BIOMATERIALS 85
TABLE 41 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 85
TABLE 42 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 85
TABLE 43 BIOMATERIALS MARKET, BY REGION, 2018–2020 (USD MILLION) 86
TABLE 44 BIOMATERIALS MARKET, BY REGION, 2021–2027 (USD MILLION) 86
6.3.1 NERVE CONDUITS 86
6.3.1.1 Increasing research in the field of nerve repair to support segment growth 86
TABLE 45 NERVE CONDUITS OFFERED BY SOME MARKET PLAYERS 87
TABLE 46 NERVE CONDUITS MARKET, BY REGION, 2018–2020 (USD MILLION) 87
TABLE 47 NERVE CONDUITS MARKET, BY REGION, 2021–2027 (USD MILLION) 87
6.3.2 NERVE WRAPS 88
6.3.2.1 Increasing incidence of peripheral injuries to drive the growth of this segment 88
TABLE 48 NERVE WRAPS OFFERED BY SOME MARKET PLAYERS 88
TABLE 49 NERVE WRAPS MARKET, BY REGION, 2018–2020 (USD MILLION) 88
TABLE 50 NERVE WRAPS MARKET, BY REGION, 2021–2027 (USD MILLION) 88
7 NERVE REPAIR & REGENERATION MARKET, BY APPLICATION 89
7.1 INTRODUCTION 90
7.2 NEUROSTIMULATION & NEUROMODULATION 90
TABLE 51 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE,
2018–2020 (USD MILLION) 90
TABLE 52 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE,
2021–2027 (USD MILLION) 90
TABLE 53 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2018–2020 (USD MILLION) 91
TABLE 54 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2021–2027 (USD MILLION) 91
7.2.1 INTERNAL NEUROSTIMULATION & NEUROMODULATION 91
7.2.1.1 Minimally invasive nature and reversibility to support the growth of this segment 91
TABLE 55 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018–2020 (USD MILLION) 91
TABLE 56 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021–2027 (USD MILLION) 92
7.2.2 EXTERNAL NEUROSTIMULATION & NEUROMODULATION 92
7.2.2.1 Rising cases of noninvasive procedures to ensure the growth of this segment 92
TABLE 57 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018–2020 (USD MILLION) 92
TABLE 58 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021–2027 (USD MILLION) 92
7.3 NERVE REPAIR & REGENERATION BIOMATERIALS 93
TABLE 59 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE,
2018–2020 (USD MILLION) 93
TABLE 60 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE,
2021–2027 (USD MILLION) 93
7.3.1 DIRECT NERVE REPAIR/NEURORRHAPHY 93
TABLE 61 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE,
2018–2020 (USD MILLION) 93
TABLE 62 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE,
2021–2027 (USD MILLION) 94
TABLE 63 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION,
2018–2020 (USD MILLION) 94
TABLE 64 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION,
2021–2027 (USD MILLION) 94
7.3.1.1 Epineural repair 94
7.3.1.1.1 Short operating times, ease, and minimal suturing requirements to drive the growth of this segment 94
TABLE 65 EPINEURAL REPAIR MARKET, BY REGION, 2018–2020 (USD MILLION) 95
TABLE 66 EPINEURAL REPAIR MARKET, BY REGION, 2021–2027 (USD MILLION) 95
7.3.1.2 Perineural repair 95
7.3.1.2.1 Perineural repair is a highly complex surgery, which has affected its prospects in this market 95
TABLE 67 PERINEURAL REPAIR MARKET, BY REGION, 2018–2020 (USD MILLION) 95
TABLE 68 PERINEURAL REPAIR MARKET, BY REGION, 2021–2027 (USD MILLION) 96
7.3.1.3 Group fascicular repair 96
7.3.1.3.1 Long procedural time to restrain the growth of this market 96
TABLE 69 GROUP FASCICULAR REPAIR MARKET, BY REGION,
2018–2020 (USD MILLION) 96
TABLE 70 GROUP FASCICULAR REPAIR MARKET, BY REGION,
2021–2027 (USD MILLION) 96
7.3.2 NERVE GRAFTING 97
TABLE 71 NERVE GRAFTING MARKET, BY TYPE, 2018–2020 (USD MILLION) 97
TABLE 72 NERVE GRAFTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 97
TABLE 73 NERVE GRAFTING MARKET, BY REGION, 2018–2020 (USD MILLION) 97
TABLE 74 NERVE GRAFTING MARKET, BY REGION, 2021–2027 (USD MILLION) 98
7.3.2.1 Autografts 98
7.3.2.1.1 Autografts are considered the gold standard for nerve gap treatment 98
TABLE 75 AUTOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 98
TABLE 76 AUTOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 99
7.3.2.2 Allografts 99
7.3.2.2.1 Benefits of allografts over autograft usage to drive the growth of this segment 99
TABLE 77 ALLOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 99
TABLE 78 ALLOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 99
7.3.2.3 Xenografts 100
7.3.2.3.1 Need for immunosuppression associated with xenograft use to restrain the growth of this segment 100
TABLE 79 XENOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 100
TABLE 80 XENOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 100
7.3.3 STEM CELL THERAPY 100
7.3.3.1 The high future growth prospects counterbalance the low penetration of stem cell therapy 100
TABLE 81 STEM CELL THERAPY MARKET, BY REGION, 2018–2020 (USD MILLION) 101
TABLE 82 STEM CELL THERAPY MARKET, BY REGION, 2021–2027 (USD MILLION) 101
8 NERVE REPAIR & REGENERATION MARKET, BY REGION 102
8.1 INTRODUCTION 103
TABLE 83 NERVE REPAIR & REGENERATION MARKET, BY REGION,
2018–2020 (USD MILLION) 103
TABLE 84 NERVE REPAIR & REGENERATION MARKET, BY REGION,
2021–2027 (USD MILLION) 103
8.2 NORTH AMERICA 104
TABLE 85 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018–2020 (USD MILLION) 105
TABLE 86 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021–2027 (USD MILLION) 106
TABLE 87 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018–2020 (USD MILLION) 106
TABLE 88 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 106
TABLE 89 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 106
TABLE 90 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 107
TABLE 91 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 107
TABLE 92 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 107
TABLE 93 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 107
TABLE 94 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 108
TABLE 95 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 108
TABLE 96 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 108
TABLE 97 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION,
2018–2020 (USD MILLION) 109
TABLE 98 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION,
2021–2027 (USD MILLION) 109
TABLE 99 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 109
TABLE 100 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 109
TABLE 101 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 110
TABLE 102 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 110
TABLE 103 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 110
TABLE 104 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 110
TABLE 105 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE,
2018–2020 (USD MILLION) 111
TABLE 106 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE,
2021–2027 (USD MILLION) 111
8.2.1 US 111
8.2.1.1 The high prevalence of neurological disorders drives the demand for nerve repair & regeneration products in the US 111
TABLE 107 COMPANY PRODUCTS THAT RECEIVED FDA APPROVAL IN THE US 112
TABLE 108 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 112
TABLE 109 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 113
TABLE 110 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 113
TABLE 111 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 113
TABLE 112 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 114
TABLE 113 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 114
TABLE 114 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 114
TABLE 115 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 114
8.2.2 CANADA 115
8.2.2.1 Rising health expenditure and increasing disease prevalence will drive market growth 115
TABLE 116 NEUROLOGICAL CONDITIONS IN CANADA 115
TABLE 117 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 116
TABLE 118 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 116
TABLE 119 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 117
TABLE 120 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 117
TABLE 121 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 117
TABLE 122 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 118
TABLE 123 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 118
TABLE 124 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 118
8.3 EUROPE 118
TABLE 125 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION,
2018–2020 (USD MILLION) 119
TABLE 126 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION,
2021–2027 (USD MILLION) 120
TABLE 127 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2018–2020 (USD MILLION) 120
TABLE 128 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 120
TABLE 129 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 121
TABLE 130 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 121
TABLE 131 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 121
TABLE 132 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 122
TABLE 133 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 122
TABLE 134 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 122
TABLE 135 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 123
TABLE 136 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 123
TABLE 137 EUROPE: BIOMATERIALS MARKET, BY REGION, 2018–2020 (USD MILLION) 123
TABLE 138 EUROPE: BIOMATERIALS MARKET, BY REGION, 2021–2027 (USD MILLION) 124
TABLE 139 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 124
TABLE 140 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 124
TABLE 141 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 124
TABLE 142 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 125
TABLE 143 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 125
TABLE 144 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 125
TABLE 145 EUROPE: BIOMATERIALS MARKET, BY APPLICATION,
2018–2020 (USD MILLION) 126
TABLE 146 EUROPE: BIOMATERIALS MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 126
8.3.1 GERMANY 126
8.3.1.1 Rising healthcare expenditure and favorable reimbursement policies to ensure strong market growth 126
TABLE 147 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 127
TABLE 148 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 127
TABLE 149 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 127
TABLE 150 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 128
TABLE 151 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 128
TABLE 152 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 128
TABLE 153 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 129
TABLE 154 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 129
8.3.2 UK 129
8.3.2.1 Government initiatives to drive the growth of the nerve repair & regeneration market in the UK 129
TABLE 155 PRODUCTS RECEIVED CE APPROVAL 130
TABLE 156 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 130
TABLE 157 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 130
TABLE 158 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 131
TABLE 159 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 131
TABLE 160 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 131
TABLE 161 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 132
TABLE 162 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 132
TABLE 163 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 132
8.3.3 FRANCE 132
8.3.3.1 Favorable healthcare reforms to support the market growth in France 132
TABLE 164 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 133
TABLE 165 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 133
TABLE 166 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 133
TABLE 167 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 134
TABLE 168 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 134
TABLE 169 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 134
TABLE 170 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 135
TABLE 171 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 135
8.3.4 ITALY 135
8.3.4.1 Easy access to healthcare services has supported the demand for nerve repair & regeneration products in Italy 135
TABLE 172 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 136
TABLE 173 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 136
TABLE 174 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 136
TABLE 175 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 137
TABLE 176 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 137
TABLE 177 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 137
TABLE 178 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 138
TABLE 179 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 138
8.3.5 SPAIN 138
8.3.5.1 The growing geriatric population and the subsequent increase in the incidence of neurological disorders drive the market growth 138
TABLE 180 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 139
TABLE 181 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 139
TABLE 182 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 139
TABLE 183 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 140
TABLE 184 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 140
TABLE 185 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 140
TABLE 186 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 141
TABLE 187 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 141
8.3.6 REST OF EUROPE 141
TABLE 188 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2017 VS. 2050 142
TABLE 189 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 142
TABLE 190 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 142
TABLE 191 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 143
TABLE 192 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 143
TABLE 193 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 143
TABLE 194 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 144
TABLE 195 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 144
TABLE 196 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 144
8.4 ASIA PACIFIC 144
TABLE 197 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018–2020 (USD MILLION) 145
TABLE 198 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021–2027 (USD MILLION) 146
TABLE 199 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018–2020 (USD MILLION) 146
TABLE 200 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 146
TABLE 201 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 146
TABLE 202 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 147
TABLE 203 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 147
TABLE 204 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 147
TABLE 205 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 148
TABLE 206 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 148
TABLE 207 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 148
TABLE 208 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 149
TABLE 209 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION,
2018–2020 (USD MILLION) 149
TABLE 210 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION,
2021–2027 (USD MILLION) 149
TABLE 211 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 149
TABLE 212 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 150
TABLE 213 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 150
TABLE 214 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 150
TABLE 215 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION,
2018–2020 (USD MILLION) 150
TABLE 216 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 151
8.4.1 JAPAN 151
8.4.1.1 Japan dominates the Asia Pacific market for nerve repair & regeneration due to its high geriatric population 151
TABLE 217 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 152
TABLE 218 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 152
TABLE 219 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 152
TABLE 220 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 153
TABLE 221 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 153
TABLE 222 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 153
TABLE 223 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 154
TABLE 224 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 154
8.4.2 CHINA 154
8.4.2.1 Rising healthcare expenditure and growing disease prevalence to ensure strong market growth 154
FIGURE 28 CHINA: CURRENT HEALTH EXPENDITURE PER CAPITA (CURRENT USD) 155
TABLE 225 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 155
TABLE 226 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 155
TABLE 227 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 156
TABLE 228 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 156
TABLE 229 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 156
TABLE 230 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 157
TABLE 231 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 157
TABLE 232 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 157
8.4.3 INDIA 157
8.4.3.1 Changing government policies to have a positive impact on the market growth for nerve repair & regeneration 157
TABLE 233 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 158
TABLE 234 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 158
TABLE 235 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 159
TABLE 236 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 159
TABLE 237 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 159
TABLE 238 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 160
TABLE 239 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 160
TABLE 240 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 160
8.4.4 REST OF ASIA PACIFIC (ROAPAC) 160
TABLE 241 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 161
TABLE 242 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 161
TABLE 243 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 162
TABLE 244 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 162
TABLE 245 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 162
TABLE 246 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 163
TABLE 247 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 163
TABLE 248 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 163

　

ページTOPに戻る


　

Summary

The global nerve repair & regeneration market is expected to reach USD 11.6 billion by 2027 from USD 6.5 billion in 2022, at a CAGR of 12.1%. The growth in this market is driven by increasing research expenditure on the neurological disorders by the government, the increasing R&D investments by the market players into the neuromodulation and neurostimulation devices and the biomaterials. Also, the expanding geriatric population base dries the growth of the market by placing more demand of the nerve repair and regeneration products.

“The biomaterial as segment is anticipated to grow at the fastest growth rate during the forecast period.”
Based on product type, the nerve repair and regenerations market is segmented into neurostimulation and neuromodulation devices and biomaterials. The biomaterials segment is expected to register the highest CAGR which is driven by the research investments, and R&D expenditure by the government and market players.

“The internal neurostimulation and neuromodulation segment is accounted for the largest share during the analysis period.”
Based on the neurostimulation and neuromodulation application, the nerve repair & regeneration market is segmented the neurostimulation and neuromodulation devices market is segmented into internal neurostimulation and neuromodulation applications and external neurostimulation and neuromodulation applications. The internal neurostimulation neuromodulation segment is held the largest share during the forecast period owing to the rising cases of nerve related injuries and the high incidence of neurological disorders.

“Asia Pacific is estimated to register the highest CAGR during the study period. North America is expected to dominate the market share”
In this report, the nerve repair & regeneration market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (Middle East & Africa and Latin America). In 2021, North America held the largest share of the market owing to the presence of the leading players and advanced healthcare infrastructure.
The market in Asia Pacific is projected to grow at the highest growth rate during the forecast period owing to the massive population base, increasing economical growth, improving healthcare infrastructure and healthcare expenditure, high reverence of the neurologic diseases and the rising demand

Breakdown of primary supply-side interviews, by company type, designation, and region:
• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)
• By Designation: C-level (30%), Director-level (34%), and Others (36%)
• By Region: North America (50%), Europe (32%), AsiaPacific (10%), and Rest of the World (8%)

List of players profiled in this report:
• Medtronic, plc. (Ireland)
• Boston Scientific Corporation (US),
• Abbott Laboratories (US)
• Axogen Corporation (US)
• Baxter (US)
• LivaNova PLC (UK)
• Integra LifeSciences (US)
• Neuronetics Inc. (US)
• Nevro Corp (US)
• NeuroPace Inc. (US)
• Polyganics (Netherlands)
• Soterix Medical Inc (US)
• Synapse Biomedical Inc. (US)
• Aleva Neurotherapeutics SA (Switzerland)
• Collagen Matrix Inc. (US)
• KeriMedical (Switzerland)
• BioWaveGO USA (US)
• NeuroSigma Inc. (US)
• tVNS Technologies GmbH (Germany)
• GiMer Medical (Taiwan)
• Checkpoint Surgical Inc. (US)
• Renishaw PLC (UK)
• Alafair Biosciences, Inc. (US)
• electroCore, Inc. (US)

Research Coverage
This report studies the nerve repair & regeneration market based on product, application and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total nerve repair & regeneration market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the nerve repair and regeneration offered by the top 16 players in the market. The report analyzes the nerve repair & regeneration market by product and region
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various nerve repair and regeneration across key geographic regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nerve repair & regeneration market
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the nerve repair & regeneration market



ページTOPに戻る


Table of Contents

1 INTRODUCTION 37
1.1 OBJECTIVES OF THE STUDY 37
1.2 MARKET DEFINITION 37
TABLE 1 INCLUSIONS & EXCLUSIONS OF THE STUDY 37
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
FIGURE 1 NERVE REPAIR & REGENERATION MARKET SEGMENTATION 38
1.3.2 YEARS CONSIDERED FOR THE STUDY 38
1.4 CURRENCY 39
TABLE 2 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 39
1.5 STAKEHOLDERS 39
1.6 SUMMARY OF CHANGES MADE 39
1.7 LIMITATIONS 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 2 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 41
2.1.1.1 Key data from secondary sources 42
2.1.2 PRIMARY DATA 43
2.1.2.1 Key data from primary sources 43
TABLE 3 KEY DATA FROM PRIMARY SOURCES 44
2.1.2.2 Key industry insights 45
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 45
2.2 MARKET SIZE ESTIMATION 46
FIGURE 4 NERVE REPAIR & REGENERATION MARKET – REVENUE SHARE ANALYSIS ILLUSTRATION: MEDTRONIC PLC 47
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH (SUPPLY SIDE): COLLECTIVE REVENUE OF NERVE REPAIR & REGENERATION PRODUCTS 48
FIGURE 6 CAGR PROJECTIONS 49
FIGURE 7 TOP-DOWN APPROACH 50
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
FIGURE 8 DATA TRIANGULATION 51
2.4 MARKET SHARE ANALYSIS 52
2.5 ASSUMPTIONS FOR THE STUDY 52
2.6 INDICATORS AND ASSUMPTIONS AND THEIR IMPACT ON THE STUDY 52
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS 53
2.7 RISK ASSESSMENT 53
TABLE 4 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54
FIGURE 9 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2022 VS. 2027 (USD BILLION) 54
4 PREMIUM INSIGHTS 59
4.1 NERVE REPAIR & REGENERATION MARKET OVERVIEW 59
4.2 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT & COUNTRY (2021) 59
4.3 NERVE REPAIR & REGENERATION MARKET, BY REGION (2022 VS. 2027) 60
FIGURE 19 NORTH AMERICA TO DOMINATE THE NERVE REPAIR & REGENERATION MARKET DURING THE FORECAST PERIOD 60
4.4 NERVE REPAIR & REGENERATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
5 MARKET OVERVIEW 61
5.1 INTRODUCTION 61
5.2 MARKET DYNAMICS 61
FIGURE 21 NERVE REPAIR & REGENERATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 61
5.2.1.1 High incidence of nerve injuries 61
5.2.1.2 Rising focus on neuromodulation & neurostimulation technologies 62
5.2.1.3 Rising geriatric population and the subsequent increase in the prevalence of neurological disorders 62
5.2.1.4 Rising government support for research on neurological disorders 63
FIGURE 22 FUNDING FOR RESEARCH BY THE NIH (US) 63
5.2.2 OPPORTUNITIES 64
5.2.2.1 Emerging markets 64
FIGURE 23 GROWTH IN CURRENT HEALTHCARE EXPENDITURE PER CAPITA, 2012–2019 64
5.2.2.2 Advances in stem cell therapy in nerve repair & regeneration 64
5.2.2.3 Growing research projects in neurology 65
FIGURE 24 RESEARCH PAPERS PUBLISHED (2011-2021) 65
TABLE 5 INDICATIVE LIST: NEUROMODULATION CLINICAL TRAILS 65
5.2.3 CHALLENGES 66
5.2.3.1 Donor-site morbidity 66
5.2.3.2 Difficulties in treating large nerve gaps 66
5.2.3.3 Stringent regulatory frameworks and time-consuming approval processes 66
5.2.3.4 Greater preference for drug therapies over nerve repair & regeneration products 66
5.2.3.5 Shortage of trained professionals 66
5.2.3.6 Product recalls 67
TABLE 6 MAJOR PRODUCT RECALLS 67
5.3 IMPACT OF COVID-19 ON THE NERVE REPAIR & REGENERATION MARKET 67
FIGURE 25 REVENUE OF NEUROMODULATION SEGMENT BY THE TOP THREE PLAYERS, 2019-2021 (USD MILLION) 68
5.4 PRICING ANALYSIS 69
TABLE 7 AVERAGE SELLING PRICES OF NERVE WRAP AND NERVE CONDUIT 69
TABLE 8 AVERAGE SELLING PRICES OF NERVE WRAP OF KEY COMPANIES 69
TABLE 9 AVERAGE SELLING PRICES OF NERVE CONDUITS OF KEY COMPANIES 69
6 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT 70
6.1 INTRODUCTION 71
TABLE 10 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2018–2020 (USD MILLION) 71
TABLE 11 NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 71
6.2 NEUROSTIMULATION AND NEUROMODULATION DEVICES 71
TABLE 12 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 72
TABLE 13 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 72
TABLE 14 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 72
TABLE 15 NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 72
6.2.1 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 73
TABLE 16 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 73
TABLE 17 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 73
TABLE 18 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 74
TABLE 19 INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 74
6.2.1.1 Spinal cord stimulation devices 74
6.2.1.1.1 Increasing incidence of spinal cord injuries to support the growth of this segment 74
TABLE 20 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 75
TABLE 21 SPINAL CORD STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 75
6.2.1.2 Deep brain stimulation devices 76
6.2.1.2.1 Rising incidence of neurodegenerative diseases among the senior population drives the growth of this segment 76
TABLE 22 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 76
TABLE 23 DEEP BRAIN STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 77
6.2.1.3 Vagus nerve stimulation devices 77
6.2.1.3.1 Increasing incidence of epilepsy to support the market growth for VNS devices 77
TABLE 24 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 77
TABLE 25 VAGUS NERVE STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 78
6.2.1.4 Sacral nerve stimulation devices 78
6.2.1.4.1 Increasing incidence of urological disorders to drive the growth of this segment 78
TABLE 26 SACRAL NERVE STIMULATION DEVICES OFFERED BY SOME MARKET PLAYERS 78
TABLE 27 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 79
TABLE 28 SACRAL NERVE STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 79
6.2.1.5 Gastric electrical stimulation devices 79
6.2.1.5.1 GES is mainly used for the treatment of GERD and gastroparesis 79
TABLE 29 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION,
2018–2020 (USD MILLION) 80
TABLE 30 GASTRIC ELECTRICAL STIMULATION DEVICES MARKET, BY REGION,
2021–2027 (USD MILLION) 80
6.2.2 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES 80
TABLE 31 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 80
TABLE 32 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 81
TABLE 33 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION BY REGION, 2018–2020 (USD MILLION) 81
TABLE 34 EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 81
6.2.2.1 Transcutaneous electrical nerve stimulation devices 82
6.2.2.1.1 Extensive use in healthcare and low costs to support the growth of this segment 82
TABLE 35 TENS DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 82
TABLE 36 TENS DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 83
6.2.2.2 Transcranial Magnetic Stimulation Devices 83
6.2.2.2.1 Minimal patient discomfort associated with TMS to support the adoption of TMS devices 83
TABLE 37 TMS DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 83
TABLE 38 TMS DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 84
6.2.2.3 Respiratory Electric Stimulation Devices 84
6.2.2.3.1 Increasing incidence of spinal cord injuries to support the growth of this segment 84
TABLE 39 RES DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 84
TABLE 40 RES DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 85
6.3 BIOMATERIALS 85
TABLE 41 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 85
TABLE 42 BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 85
TABLE 43 BIOMATERIALS MARKET, BY REGION, 2018–2020 (USD MILLION) 86
TABLE 44 BIOMATERIALS MARKET, BY REGION, 2021–2027 (USD MILLION) 86
6.3.1 NERVE CONDUITS 86
6.3.1.1 Increasing research in the field of nerve repair to support segment growth 86
TABLE 45 NERVE CONDUITS OFFERED BY SOME MARKET PLAYERS 87
TABLE 46 NERVE CONDUITS MARKET, BY REGION, 2018–2020 (USD MILLION) 87
TABLE 47 NERVE CONDUITS MARKET, BY REGION, 2021–2027 (USD MILLION) 87
6.3.2 NERVE WRAPS 88
6.3.2.1 Increasing incidence of peripheral injuries to drive the growth of this segment 88
TABLE 48 NERVE WRAPS OFFERED BY SOME MARKET PLAYERS 88
TABLE 49 NERVE WRAPS MARKET, BY REGION, 2018–2020 (USD MILLION) 88
TABLE 50 NERVE WRAPS MARKET, BY REGION, 2021–2027 (USD MILLION) 88
7 NERVE REPAIR & REGENERATION MARKET, BY APPLICATION 89
7.1 INTRODUCTION 90
7.2 NEUROSTIMULATION & NEUROMODULATION 90
TABLE 51 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE,
2018–2020 (USD MILLION) 90
TABLE 52 NEUROSTIMULATION & NEUROMODULATION MARKET, BY TYPE,
2021–2027 (USD MILLION) 90
TABLE 53 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2018–2020 (USD MILLION) 91
TABLE 54 NEUROSTIMULATION & NEUROMODULATION APPLICATIONS, BY REGION, 2021–2027 (USD MILLION) 91
7.2.1 INTERNAL NEUROSTIMULATION & NEUROMODULATION 91
7.2.1.1 Minimally invasive nature and reversibility to support the growth of this segment 91
TABLE 55 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018–2020 (USD MILLION) 91
TABLE 56 INTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021–2027 (USD MILLION) 92
7.2.2 EXTERNAL NEUROSTIMULATION & NEUROMODULATION 92
7.2.2.1 Rising cases of noninvasive procedures to ensure the growth of this segment 92
TABLE 57 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2018–2020 (USD MILLION) 92
TABLE 58 EXTERNAL NEUROSTIMULATION & NEUROMODULATION MARKET, BY REGION, 2021–2027 (USD MILLION) 92
7.3 NERVE REPAIR & REGENERATION BIOMATERIALS 93
TABLE 59 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE,
2018–2020 (USD MILLION) 93
TABLE 60 NERVE REPAIR & REGENERATION BIOMATERIALS MARKET, BY TYPE,
2021–2027 (USD MILLION) 93
7.3.1 DIRECT NERVE REPAIR/NEURORRHAPHY 93
TABLE 61 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE,
2018–2020 (USD MILLION) 93
TABLE 62 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY TYPE,
2021–2027 (USD MILLION) 94
TABLE 63 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION,
2018–2020 (USD MILLION) 94
TABLE 64 DIRECT NERVE REPAIR/NEURORRHAPHY MARKET, BY REGION,
2021–2027 (USD MILLION) 94
7.3.1.1 Epineural repair 94
7.3.1.1.1 Short operating times, ease, and minimal suturing requirements to drive the growth of this segment 94
TABLE 65 EPINEURAL REPAIR MARKET, BY REGION, 2018–2020 (USD MILLION) 95
TABLE 66 EPINEURAL REPAIR MARKET, BY REGION, 2021–2027 (USD MILLION) 95
7.3.1.2 Perineural repair 95
7.3.1.2.1 Perineural repair is a highly complex surgery, which has affected its prospects in this market 95
TABLE 67 PERINEURAL REPAIR MARKET, BY REGION, 2018–2020 (USD MILLION) 95
TABLE 68 PERINEURAL REPAIR MARKET, BY REGION, 2021–2027 (USD MILLION) 96
7.3.1.3 Group fascicular repair 96
7.3.1.3.1 Long procedural time to restrain the growth of this market 96
TABLE 69 GROUP FASCICULAR REPAIR MARKET, BY REGION,
2018–2020 (USD MILLION) 96
TABLE 70 GROUP FASCICULAR REPAIR MARKET, BY REGION,
2021–2027 (USD MILLION) 96
7.3.2 NERVE GRAFTING 97
TABLE 71 NERVE GRAFTING MARKET, BY TYPE, 2018–2020 (USD MILLION) 97
TABLE 72 NERVE GRAFTING MARKET, BY TYPE, 2021–2027 (USD MILLION) 97
TABLE 73 NERVE GRAFTING MARKET, BY REGION, 2018–2020 (USD MILLION) 97
TABLE 74 NERVE GRAFTING MARKET, BY REGION, 2021–2027 (USD MILLION) 98
7.3.2.1 Autografts 98
7.3.2.1.1 Autografts are considered the gold standard for nerve gap treatment 98
TABLE 75 AUTOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 98
TABLE 76 AUTOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 99
7.3.2.2 Allografts 99
7.3.2.2.1 Benefits of allografts over autograft usage to drive the growth of this segment 99
TABLE 77 ALLOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 99
TABLE 78 ALLOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 99
7.3.2.3 Xenografts 100
7.3.2.3.1 Need for immunosuppression associated with xenograft use to restrain the growth of this segment 100
TABLE 79 XENOGRAFTS MARKET, BY REGION, 2018–2020 (USD MILLION) 100
TABLE 80 XENOGRAFTS MARKET, BY REGION, 2021–2027 (USD MILLION) 100
7.3.3 STEM CELL THERAPY 100
7.3.3.1 The high future growth prospects counterbalance the low penetration of stem cell therapy 100
TABLE 81 STEM CELL THERAPY MARKET, BY REGION, 2018–2020 (USD MILLION) 101
TABLE 82 STEM CELL THERAPY MARKET, BY REGION, 2021–2027 (USD MILLION) 101
8 NERVE REPAIR & REGENERATION MARKET, BY REGION 102
8.1 INTRODUCTION 103
TABLE 83 NERVE REPAIR & REGENERATION MARKET, BY REGION,
2018–2020 (USD MILLION) 103
TABLE 84 NERVE REPAIR & REGENERATION MARKET, BY REGION,
2021–2027 (USD MILLION) 103
8.2 NORTH AMERICA 104
TABLE 85 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018–2020 (USD MILLION) 105
TABLE 86 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021–2027 (USD MILLION) 106
TABLE 87 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018–2020 (USD MILLION) 106
TABLE 88 NORTH AMERICA: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 106
TABLE 89 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 106
TABLE 90 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 107
TABLE 91 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 107
TABLE 92 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 107
TABLE 93 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 107
TABLE 94 NORTH AMERICA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 108
TABLE 95 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 108
TABLE 96 NORTH AMERICA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 108
TABLE 97 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION,
2018–2020 (USD MILLION) 109
TABLE 98 NORTH AMERICA: BIOMATERIALS MARKET, BY REGION,
2021–2027 (USD MILLION) 109
TABLE 99 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 109
TABLE 100 NORTH AMERICA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 109
TABLE 101 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 110
TABLE 102 NORTH AMERICA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 110
TABLE 103 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY,
2018–2020 (USD MILLION) 110
TABLE 104 NORTH AMERICA: BIOMATERIALS MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 110
TABLE 105 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE,
2018–2020 (USD MILLION) 111
TABLE 106 NORTH AMERICA: BIOMATERIALS MARKET, BY TYPE,
2021–2027 (USD MILLION) 111
8.2.1 US 111
8.2.1.1 The high prevalence of neurological disorders drives the demand for nerve repair & regeneration products in the US 111
TABLE 107 COMPANY PRODUCTS THAT RECEIVED FDA APPROVAL IN THE US 112
TABLE 108 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 112
TABLE 109 US: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 113
TABLE 110 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 113
TABLE 111 US: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 113
TABLE 112 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 114
TABLE 113 US: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 114
TABLE 114 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 114
TABLE 115 US: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 114
8.2.2 CANADA 115
8.2.2.1 Rising health expenditure and increasing disease prevalence will drive market growth 115
TABLE 116 NEUROLOGICAL CONDITIONS IN CANADA 115
TABLE 117 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 116
TABLE 118 CANADA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 116
TABLE 119 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 117
TABLE 120 CANADA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 117
TABLE 121 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 117
TABLE 122 CANADA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 118
TABLE 123 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 118
TABLE 124 CANADA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 118
8.3 EUROPE 118
TABLE 125 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION,
2018–2020 (USD MILLION) 119
TABLE 126 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY REGION,
2021–2027 (USD MILLION) 120
TABLE 127 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2018–2020 (USD MILLION) 120
TABLE 128 EUROPE: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 120
TABLE 129 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 121
TABLE 130 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 121
TABLE 131 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 121
TABLE 132 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 122
TABLE 133 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 122
TABLE 134 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 122
TABLE 135 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 123
TABLE 136 EUROPE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 123
TABLE 137 EUROPE: BIOMATERIALS MARKET, BY REGION, 2018–2020 (USD MILLION) 123
TABLE 138 EUROPE: BIOMATERIALS MARKET, BY REGION, 2021–2027 (USD MILLION) 124
TABLE 139 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 124
TABLE 140 EUROPE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 124
TABLE 141 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 124
TABLE 142 EUROPE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 125
TABLE 143 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 125
TABLE 144 EUROPE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 125
TABLE 145 EUROPE: BIOMATERIALS MARKET, BY APPLICATION,
2018–2020 (USD MILLION) 126
TABLE 146 EUROPE: BIOMATERIALS MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 126
8.3.1 GERMANY 126
8.3.1.1 Rising healthcare expenditure and favorable reimbursement policies to ensure strong market growth 126
TABLE 147 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 127
TABLE 148 GERMANY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 127
TABLE 149 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 127
TABLE 150 GERMANY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 128
TABLE 151 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 128
TABLE 152 GERMANY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 128
TABLE 153 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 129
TABLE 154 GERMANY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 129
8.3.2 UK 129
8.3.2.1 Government initiatives to drive the growth of the nerve repair & regeneration market in the UK 129
TABLE 155 PRODUCTS RECEIVED CE APPROVAL 130
TABLE 156 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 130
TABLE 157 UK: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 130
TABLE 158 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 131
TABLE 159 UK: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 131
TABLE 160 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 131
TABLE 161 UK: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 132
TABLE 162 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2018–2020 (USD MILLION) 132
TABLE 163 UK: BIOMATERIALS MARKET, BY PRODUCT TYPE, 2021–2027 (USD MILLION) 132
8.3.3 FRANCE 132
8.3.3.1 Favorable healthcare reforms to support the market growth in France 132
TABLE 164 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 133
TABLE 165 FRANCE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 133
TABLE 166 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 133
TABLE 167 FRANCE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 134
TABLE 168 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 134
TABLE 169 FRANCE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 134
TABLE 170 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 135
TABLE 171 FRANCE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 135
8.3.4 ITALY 135
8.3.4.1 Easy access to healthcare services has supported the demand for nerve repair & regeneration products in Italy 135
TABLE 172 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 136
TABLE 173 ITALY: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 136
TABLE 174 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 136
TABLE 175 ITALY: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 137
TABLE 176 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 137
TABLE 177 ITALY: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 137
TABLE 178 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 138
TABLE 179 ITALY: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 138
8.3.5 SPAIN 138
8.3.5.1 The growing geriatric population and the subsequent increase in the incidence of neurological disorders drive the market growth 138
TABLE 180 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 139
TABLE 181 SPAIN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 139
TABLE 182 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 139
TABLE 183 SPAIN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 140
TABLE 184 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 140
TABLE 185 SPAIN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 140
TABLE 186 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 141
TABLE 187 SPAIN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 141
8.3.6 REST OF EUROPE 141
TABLE 188 PERCENTAGE OF POPULATION AGED 65 YEARS OR OVER, 2017 VS. 2050 142
TABLE 189 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 142
TABLE 190 ROE: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 142
TABLE 191 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 143
TABLE 192 ROE: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 143
TABLE 193 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 143
TABLE 194 ROE: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 144
TABLE 195 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 144
TABLE 196 ROE: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 144
8.4 ASIA PACIFIC 144
TABLE 197 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2018–2020 (USD MILLION) 145
TABLE 198 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY REGION, 2021–2027 (USD MILLION) 146
TABLE 199 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2018–2020 (USD MILLION) 146
TABLE 200 ASIA PACIFIC: NERVE REPAIR & REGENERATION MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 146
TABLE 201 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2018–2020 (USD MILLION) 146
TABLE 202 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY REGION, 2021–2027 (USD MILLION) 147
TABLE 203 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 147
TABLE 204 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 147
TABLE 205 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 148
TABLE 206 ASIA PACIFIC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 148
TABLE 207 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 148
TABLE 208 ASIA PACIFIC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 149
TABLE 209 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION,
2018–2020 (USD MILLION) 149
TABLE 210 ASIA PACIFIC: BIOMATERIALS MARKET, BY REGION,
2021–2027 (USD MILLION) 149
TABLE 211 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 149
TABLE 212 ASIA PACIFIC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 150
TABLE 213 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2018–2020 (USD MILLION) 150
TABLE 214 ASIA PACIFIC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY APPLICATION, 2021–2027 (USD MILLION) 150
TABLE 215 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION,
2018–2020 (USD MILLION) 150
TABLE 216 ASIA PACIFIC: BIOMATERIALS MARKET, BY APPLICATION,
2021–2027 (USD MILLION) 151
8.4.1 JAPAN 151
8.4.1.1 Japan dominates the Asia Pacific market for nerve repair & regeneration due to its high geriatric population 151
TABLE 217 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 152
TABLE 218 JAPAN: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 152
TABLE 219 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 152
TABLE 220 JAPAN: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 153
TABLE 221 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 153
TABLE 222 JAPAN: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 153
TABLE 223 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 154
TABLE 224 JAPAN: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 154
8.4.2 CHINA 154
8.4.2.1 Rising healthcare expenditure and growing disease prevalence to ensure strong market growth 154
FIGURE 28 CHINA: CURRENT HEALTH EXPENDITURE PER CAPITA (CURRENT USD) 155
TABLE 225 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 155
TABLE 226 CHINA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 155
TABLE 227 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 156
TABLE 228 CHINA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 156
TABLE 229 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 156
TABLE 230 CHINA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 157
TABLE 231 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 157
TABLE 232 CHINA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 157
8.4.3 INDIA 157
8.4.3.1 Changing government policies to have a positive impact on the market growth for nerve repair & regeneration 157
TABLE 233 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 158
TABLE 234 INDIA: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 158
TABLE 235 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 159
TABLE 236 INDIA: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 159
TABLE 237 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 159
TABLE 238 INDIA: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 160
TABLE 239 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 160
TABLE 240 INDIA: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 160
8.4.4 REST OF ASIA PACIFIC (ROAPAC) 160
TABLE 241 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 161
TABLE 242 ROAPAC: NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 161
TABLE 243 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 162
TABLE 244 ROAPAC: INTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 162
TABLE 245 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2018–2020 (USD MILLION) 162
TABLE 246 ROAPAC: EXTERNAL NEUROSTIMULATION AND NEUROMODULATION DEVICES MARKET, BY TYPE, 2021–2027 (USD MILLION) 163
TABLE 247 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2018–2020 (USD MILLION) 163
TABLE 248 ROAPAC: BIOMATERIALS MARKET, BY PRODUCT TYPE,
2021–2027 (USD MILLION) 163

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（ケミカル）の最新刊レポート

MarketsandMarkets社のその他分野での最新刊レポート

本レポートと同じKEY WORD（repair）の最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/22　10:26

155.52 円

163.34 円

198.56 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.